Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | KDM5B |
| Gene Name: | KDM5B |
| Protein Full Name: | Lysine-specific demethylase 5B |
| Alias: | Cancer/testis antigen 31; CT31; JAD1B; Jumonji, AT rich interactive domain 1B (RBP2-like); KDM5B; Lysine (K)-specific demethylase 5B; PLU-1; PUT1; RB-binding protein; RBBP2H1A; Retinoblastoma-binding protein 2 homolog 1 |
| Mass (Da): | 175645 |
| Number AA: | 1544 |
| UniProt ID: | Q9UGL1 |
| Locus ID: | 10765 |
| COSMIC ID: | KDM5B |
| Gene location on chromosome: | 1q32.1 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | MIXED |
| Number of cancer specimens: | 19536 |
| Percent of cancer specimens with mutations: | 1.25 |
| Normal role description: | KDM5B is a lysine demethylase with specific specificity to Lysine 4 of histone H3. As KDM5B target histone proteins it has a role in epigenetic modification of genes to induce or repress transcription. KDM5B's role in cancer development is ambiguous. Increased expression was observed in breast cancer cell which correlated with repression of tumour suppressor proteins BRCA1 and HOXA5. However, a decreased expression was observed in melanomas and glioblastomas. Thus KDM5B's role appears to be context specific. |